These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30175528)

  • 1. Reward-enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention-deficit/hyperactivity disorder.
    Ide S; Ikekubo Y; Hua J; Takamatsu Y; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacol Rep; 2018 Sep; 38(3):149-153. PubMed ID: 30175528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Roles of Opioid and Dopamine Systems in Lateral Hypothalamic Intracranial Self-Stimulation.
    Ide S; Takahashi T; Takamatsu Y; Uhl GR; Niki H; Sora I; Ikeda K
    Int J Neuropsychopharmacol; 2017 May; 20(5):403-409. PubMed ID: 28031268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of dopamine transporter knockout mice as an animal model of AD/HD].
    Kasahara Y; Kubo Y; Sora I
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):185-9. PubMed ID: 25069256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.
    Leddy JJ; Waxmonsky JG; Salis RJ; Paluch RA; Gnagy EM; Mahaney P; Erbe R; Pelham WE; Epstein LH
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):127-36. PubMed ID: 19364291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
    Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
    Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder.
    Avale ME; Falzone TL; Gelman DM; Low MJ; Grandy DK; Rubinstein M
    Mol Psychiatry; 2004 Jul; 9(7):718-26. PubMed ID: 14699433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter.
    Tilley MR; Gu HH
    J Pharmacol Exp Ther; 2008 Nov; 327(2):554-60. PubMed ID: 18698001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.
    Roman T; Rohde LA; Hutz MH
    Am J Pharmacogenomics; 2004; 4(2):83-92. PubMed ID: 15059031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
    Faraone SV
    Neurosci Biobehav Rev; 2018 Apr; 87():255-270. PubMed ID: 29428394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.
    Mergy MA; Gowrishankar R; Davis GL; Jessen TN; Wright J; Stanwood GD; Hahn MK; Blakely RD
    Neurochem Int; 2014 Jul; 73():56-70. PubMed ID: 24332984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of learning and increase in dopamine level in the frontal cortex by methylphenidate in mice lacking dopamine transporter.
    Takamatsu Y; Hagino Y; Sato A; Takahashi T; Nagasawa SY; Kubo Y; Mizuguchi M; Uhl GR; Sora I; Ikeda K
    Curr Mol Med; 2015; 15(3):245-52. PubMed ID: 25817856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD).
    Vles JS; Feron FJ; Hendriksen JG; Jolles J; van Kroonenburgh MJ; Weber WE
    Neuropediatrics; 2003 Apr; 34(2):77-80. PubMed ID: 12776228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain.
    Volkow ND; Wang GJ; Fowler JS; Telang F; Maynard L; Logan J; Gatley SJ; Pappas N; Wong C; Vaska P; Zhu W; Swanson JM
    Am J Psychiatry; 2004 Jul; 161(7):1173-80. PubMed ID: 15229048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuropsychopharmacological effects of methylphenidate].
    Ikeda K; Takamatsu Y; Hagino Y; Sora I
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Jun; 29(3):121-3. PubMed ID: 19663262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment.
    del Campo N; Fryer TD; Hong YT; Smith R; Brichard L; Acosta-Cabronero J; Chamberlain SR; Tait R; Izquierdo D; Regenthal R; Dowson J; Suckling J; Baron JC; Aigbirhio FI; Robbins TW; Sahakian BJ; Müller U
    Brain; 2013 Nov; 136(Pt 11):3252-70. PubMed ID: 24163364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuropsychiatric bases of the methylphenidate-therapy of the attention deficit/hyperactivity disorder (ADHD)].
    Huber M; Kirchler E; Niederhofer H; Gruber L
    Fortschr Neurol Psychiatr; 2007 May; 75(5):275-84. PubMed ID: 17443438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between electrically-, ritalin- and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of Attention-Deficit Hyperactivity Disorder.
    Russell V; de Villiers A; Sagvolden T; Lamm M; Taljaard J
    Behav Brain Res; 1998 Jul; 94(1):163-71. PubMed ID: 9708847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.